Anti-tgf-beta receptor ii antibodies

Abstract

The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGFβRII), pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and fibrosis.

1 - 21 . (canceled) 
     
     
         22 . A method of treating cancer in a patient comprising administering to the patient an effective amount of an antibody that specifically binds human TGFβ receptor II (TGFβRII), wherein the antibody comprises the light chain amino acid sequence of SEQ ID NO: 4 and the heavy chain amino acid sequence of SEQ ID NO: 37, and wherein the cancer is breast, pancreatic, melanoma or colon. 
     
     
         23 . The method of  claim 22 , wherein the cancer is breast cancer and wherein the method further comprises administering an effective amount of cyclophosphamide to the patient simultaneously, separately or sequentially with the administration of the antibody. 
     
     
         24 . A method of treating fibrosis or fibrotic disease in a patient comprising administering to the patient an effective amount of an antibody comprising a light chain amino acid sequence of SEQ ID NO: 4 and a heavy chain amino acid sequence of SEQ ID NO: 37.